advanceCOR GmbH
Biotechnology
-
Short facts
-
- Research & Development
- Year founded 2012
- 25 Employees (site)
- Turnover: not available
Products/services: advanceCOR is a clinical drug developing company, focusing on novel therapeutics and diagnostics for the treatment of heart and vascular diseases. The focus is on the personalized treatment of cardiovascular diseases with large unmet medical need. We provide truly innovative treatments with a companion diagnostic. advanceCOR´s activities and experiences comprise all steps from research to clinical drug development and commercialization. One project (Revacept) is in the phase II study at different university hospitals. One project is in the preclinical phase (COR-2) and others in the scientific test stage (COR-3). advanceCOR carries out GLP-certified measurements of substances in buffer and serum for preclinical and clinical drug development. advanceCOR has also received a good manufacturing practice (GMP) certificate to carry out analytical studies, and has been granted the status of a drug manufacturer. advanceCOR is a clinical drug developing company, focusing on novel therapeutics and diagnostics for the treatment of heart and vascular diseases. The focus is on the personalized treatment of cardiovascular diseases with large unmet medical need. We provide truly innovative treatments with a companion diagnostic. advanceCOR´s activities and experiences comprise all steps from research to clinical drug development and commercialization. One project (Revacept) is in the phase II study at different university hospitals. One project is in the preclinical phase (COR-2) and others in the scientific test stage (COR-3). advanceCOR… read more
Basic data
Company
advanceCOR GmbH
Street
Fraunhoferstr. 9a
PC / City
82152 Planegg
County
Upper Bavaria
Phone
+49 89 2000204-10
Fax
+49 89 2000204-20
Homepage
Language skills
English, German
Contact person
Management: Prof. Dr. Götz Münch (Mr.)
Management: Prof. Dr. Martin Ungerer (Mr.)
Profile/competences
Core competencies
Product development
Revacept
GPVI inhibiting antibodies
COR-2
Key sectors / sub-sectors
- Biotechnology: Therapeutic drug development
NACE industries
- Scientific research and development 72
- Research and experimental development on natural sciences and engineering 72.1
- Research and experimental development on biotechnology 72.11
Certifications
not available
Sales markets - target industries
not available
Sales markets - target countries
not available
Cooperation offers
not available